



CLAIMS:

1. A compound of general formula (I)



in which


- 5 R^1 represents a group of the formula



in which

$\#^1$ represents the point of attachment to the nitrogen atom,

Ar represents a group of the formula



10

in which

$\#^2$ represents the point of attachment to the nitrogen atom,


R^{2A} represents a group selected from a chlorine atom, a bromine atom, trifluoromethyl, trifluoromethoxy, ethoxycarbonyl and $-C(=O)NH_2$,

- 15 R^{2B} represents a group selected from a chlorine atom, trifluoromethyl, and ethoxycarbonyl,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

2. A compound of general formula (I) according to Claim 1, wherein


R^1 represents a group of the formula



in which

#¹ represents the point of attachment to the nitrogen atom,

Ar represents a group of the formula



5

in which


#² represents the point of attachment to the nitrogen atom,

R^{2A} represents a group selected from a chlorine atom, a bromine atom, trifluoromethyl, trifluoromethoxy, ethoxycarbonyl and -C(=O)NH₂,

10 or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

3. A compound of general formula (I) according to Claim 1 or 2, wherein


R¹ represents a group of the formula



in which

15 #¹ represents the point of attachment to the nitrogen atom,

Ar represents a group of the formula



in which


#² represents the point of attachment to the nitrogen atom,

R^{2A} represents a group selected from a chlorine atom, trifluoromethyl and trifluoromethoxy,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

4. A method of preparing a compound of general formula (I) according to any one of claims 1 to 3, said method comprising the step of


[A] of allowing an intermediate compound of formula (II):



in which R^1 is as defined for the compound of general formula (I) according to any one of claims 1 to 3,

- 10 R^3 represents a (C_1-C_4) -alkyl group, in particular a methyl group,


to react in a first step in the presence of a base, and optionally a copper salt, with a compound of general formula (III):



in which


- 15 R^4 represents a (C_1-C_4) -alkyl group, in particular a methyl group,

to give an intermediate compound, which is then allowed to react in the presence of a base in a second step with a hydrazine compound of general formula (IV) or a respective salt thereof



- 20 in which Ar is as defined for the compound of general formula (I) according to any one of claims 1 to 3,

thereby giving a compound of general formula (V) :




in which R¹ and Ar are as defined for the compound of general formula (I) according to any one of claims 1 to 3, and

R⁴ represents a (C₁-C₄)-alkyl group, in particular a methyl group,

5 followed by a subsequent step

[B] of allowing the compound of formula (V) obtained in step [A] to react with ammonia thereby giving a compound of general formula (I):




in which R¹ and Ar are as defined for the compound of general formula (I) according to any one of claims 1 to 3,

10

optionally followed by step


[C] conversion of the alcohols of general formula (I-A):



in which Ar is as defined for the compound of general formula (I) according to any one of claims 1 to 3,

15

to the ketones of general formula (I-B):



in which Ar is as defined for the compound of general formula (I) according to any one of claims 1 to 3,

5 using known oxidation methods,

each [A], [B] and [C] optionally followed, where appropriate, by (i) separating the compounds of formula (I) thus obtained into their respective enantiomers, and/or (ii) converting the compounds of formula (I) into their respective hydrates, solvates, salts and/or hydrates or solvates of the salts by treatment with the corresponding solvents and/or acids or bases.

5. Compound as defined in any one of Claims 1 to 3 for use in the treatment and/or prevention of diseases.

6. Compound as defined in any one of Claims 1 to 3 for use in a method for the treatment and/or prevention of acute and chronic kidney diseases including diabetic nephropathy, acute and chronic heart failure, preeclampsia, peripheral arterial disease (PAD), coronary microvascular dysfunction (CMD), Raynaud's syndrome and dysmenorrhea.

7. Use of a compound as defined in any one of Claims 1 to 3 for the manufacture of a pharmaceutical composition for the treatment and/or prevention of acute and chronic kidney diseases including diabetic nephropathy, acute and chronic heart failure, preeclampsia, peripheral arterial disease (PAD), coronary microvascular dysfunction (CMD), Raynaud's syndrome and dysmenorrhea.

8. Pharmaceutical composition comprising a compound as defined in any one of Claims 1 to 3 and one or more pharmaceutically acceptable excipients.

9. Pharmaceutical composition of Claim 8 comprising one or more first active ingredient of a compound of general formula (I) according to any one of claims 1 to 4, and one or more further active ingredients, in particular one or more additional therapeutic agents selected

10

- 10

- Nc1nc2c(ncn2C(F)(F)F)c3ccncc31CCn1c(=O)c2cc(Cl)cc2n1CC[C@H](O)C(F)(F)F

15

- 15

